Pharma
- 15% of US adults — 37 million people — are estimated to have CKD.
- Most (9 in 10) adults with CKD do not know they have it.
- 1 in 2 people with impaired kidney function who are not on dialysis does not know they have CKD.
- At least 20% of people between the ages of 65 and 74 years, and half of those older than 75 years, have chronic kidney disease. Yet, development pipelines for the ten largest pharmaceutical companies contain fewer than 30 active nephrology clinical investigations compared with more than 1,300 in oncology.
Elderly patients on dialysis in the US are expected to live for approximately 4.5 years; this is similar to that of lung cancer patients. Advancements in the kidney specialty appear to be stagnant compared to the advances in other medical specialties, heart attacks and strokes, and their management over the past decade or two. Hence, there is a need to conduct more quality clinical trials in the field of kidney disease. Randomized trials are the best method for identifying and quantifying the benefits and risks of clinical practice interventions. That is what drives us here at SCCR to conduct clinical trials to help advance the field and impact our community, which is statistically more prone to kidney disease and its predisposing conditions.
Patients benefit from the SCCR's involvement in numerous Food and Drug Administration (FDA) national clinical research trials. Providing access to these national studies keeps the community updated on renal care's latest medical and surgical advances. The FDA regulates the clinical trials offered at the SCCR to protect our patient's rights, safety, and welfare. We offer clinical trials that explore the latest treatments for Diabetes Mellitus, Chronic Kidney Disease, Gout, Hypertension, Genotyping, Systemic Lupus, Lupus Nephritis, anemia of chronic kidney disease, Vitamin D deficiency, and Dyslipidemia in dialysis and non-dialysis patient population and many others. The physicians at SCCR Orangeburg, South Carolina, have been participating in clinical trials for 20 years. South Carolina Clinical Research LLC. (SCCR) is an independent research center established in the year 2002. SCCR is associated with SC Nephrology and Hypertension Center, Inc. Our organization brings 20 years of clinical research experience. We have access to a dedicated phase 1 facility in Orangeburg, SC. We have successfully conducted several phases I, II, III, IV clinical trials. Time after time, we have been recognized as one of the high performing, high enrolling sites in the field of Renal Research. SCCR staff currently includes 3 MDs who serve as PIs/ Subs and 5 Study Coordinators who are cross-trained for studies to provide back-up support as needed. Our SCCR staff is growing as we obtain more studies to maintain and accommodate our growing studies pipeline.
SCCR also partners with Frenova Renal Research to conduct clinical trials. Frenova Renal Research, a Fresenius Medical Care North America company, is the only Phase I-IV drug and device clinical development services provider dedicated exclusively to renal research. Frenova provides access to one of the largest renal research site network in the world. SCCR is a member of the Frenova F1RST Up alliance, a highly select group of sites chosen for their renal research expertise and track record of rapid patient recruitment and retention.
SCCR is located adjacent to the Dialysis Access Institute and a 260+ bed, regional hospital in Orangeburg, South Carolina.